Michael Wayne Vermeulen, PA

Michael Vermeulen practices at Texas Oncology PA in New Braunfels, Texas.

Michael Vermeulen's NPI, 1407829872, was assigned on February 8, 2006. Michael Vermeulen holds Texas license PA04518.

Michael Vermeulen's primary practice is Texas Oncology PA, at 1448 E Common St, New Braunfels, TX 78130 in Comal County. The practice phone is (972) 997-8000.

Michael Vermeulen's primary practice is Texas Oncology PA in New Braunfels, Texas. Michael Vermeulen is also affiliated with CHRISTUS Santa Rosa Hospital - San Marcos. The medical group on file is Texas Oncology. Dmand AI also links Michael Vermeulen to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Michael Vermeulen practices, 4 sites in all. Vendor and product names are available with a free account.

Physician assistant is Michael Vermeulen's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Michael Vermeulen is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Michael Vermeulen is licensed in Texas.

Dmand AI lists depression, insomnia and tobacco use among the conditions Michael Vermeulen treats.

CMS data shows 4,692 Medicare services from Michael Vermeulen across 31 procedure codes in 2024, for 521 Medicare patients. Medicare paid $105,423 for them. Every service was in an office.

CMS counts 521 Medicare patients who saw Michael Vermeulen in 2024. The largest group is 75 to 84, with 222 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Michael Vermeulen's median patient age at 72, with 53% women.

In 2024, Michael Vermeulen wrote 395 Medicare Part D claims for 148 patients. 87% of them were for generic drugs. CMS names the drug for 287 of them, across 13 drugs with 11 or more claims each, at $66,469 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Michael Vermeulen for performance year 2024, reported through an alternative payment model (APM). Michael Vermeulen accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 22 general payments to Michael Vermeulen from 8 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Bristol-Myers Squibb Company paid the most, $247.